Inflammatory Breast CancerThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

• By Date
• Specialty Filter
• Discussions
• Top 20

Pages: 1  2  3  4  5  

GPR30 and estrogen receptor expression: new insights into hormone dependence of inflammatory breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract  GPR30 is a novel G protein-coupled estrogen receptor (ER) associated with metastases in breast cancer (BC) and poor survival in endometrial and ovarian tumors. The association of GPR30 expression with inflammatory breast cancer (IBC), an aggressive and commonly hormone-independent form of BC, has not been studied. GPR30, ER, progesterone receptor (PR), epidermal growth factor receptor (EGFR), and HER-2 expression were assessed by immunohistochemistry (and FISH for HER-2) in 88 primary IBCs. GPR30 expression was correlated with patient overall survival (OS), disease-free survival (DFS), pathologic va...
Source: Breast Cancer Research and Treatment - November 9, 2009 Category: Cancer & Oncology Tags: breast cancer Research and Treatment Source Type: journals

A unique proteolytic fragment of alpha1-antitrypsin is elevated in ductal fluid of breast cancer patientEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In conclusion, elevated C-41/42 is likely the result of elevated AAT synthesis, and the activity of specific MMPs present within the tumor. As other C-terminal fragments of AAT are reported to function as tumor-derived suppressors to the host immune-system, elevated C-41/42 may also be predictive of a poor outcome. Content Type Journal ArticleCategory Preclinical studyDOI 10.1007/s10549-009-0625-5Authors Junma Zhou, Johns Hopkins Medical Institutions Department of Pathology Baltimore MD 21287 USABruce Trock, Johns Hopkins Medical Institutions Department of Urology Baltimore MD 21287 USATheodore N. Tsangaris, Johns H...
Source: Breast Cancer Research and Treatment - November 9, 2009 Category: Cancer & Oncology Tags: breast cancer Research and Treatment Source Type: journals

FDG-PET/CT useful for initial staging of inflammatory breast cancer patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Eighteen-fluorodeoxyglucose positron emission tomography/computed tomography imaging provides invaluable information regarding nodal status or distant metastases in inflammatory breast cancer patients and should be considered for initial staging, say researchers. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - November 2, 2009 Category: Cancer & Oncology Source Type: news

FDG-PET/CT useful for initial staging of inflammatory breast cancer patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Eighteen-fluorodeoxyglucose positron emission tomography/computed tomography imaging provides invaluable information regarding nodal status or distant metastases in inflammatory breast cancer patients and should be considered for initial staging, say researchers. (Source: MedWire News - Breast Cancer)
Source: MedWire News - Breast Cancer - November 2, 2009 Category: Cancer & Oncology Source Type: news

Diane Foresee SurvivorEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Breast cancer survivor Diane Foresee has dealt with two different types of breast cancer: invasive ductal carcinoma and inflammatory breast cancer. She faced her fears, educated herself, and plunged into chemotherapy, radiation, and Herceptin treatments. Diane is a woman of faith, and here she tells her breast cancer survivor story. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - October 31, 2009 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: consumer

Circulating tumor cells in metastatic inflammatory breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Metastatic IBC patients had a lower prevalence and fewer CTCs in comparison to metastatic non-IBC patients. Survival of metastatic IBC patients with <5 CTCs was not significantly better than that of patients with ≥5 CTCs. Further research is warranted with prospective assessment of CTCs in IBC patients and their biological characterization. (Source: Annals of Oncology)
Source: Annals of Oncology - October 27, 2009 Category: Cancer & Oncology Authors: Mego, M., De Giorgi, U., Hsu, L., Ueno, N. T., Valero, V., Jackson, S., Andreopoulou, E., Kau, S.-W., Reuben, J. M., Cristofanilli, M. Tags: breast cancer Source Type: journals

Nitrative and Oxidative Stress in Toxicology and DiseaseEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Persistent inflammation and the generation of reactive oxygen and nitrogen species play pivotal roles in tissue injury during disease pathogenesis and as a reaction to toxicant exposures. The associated oxidative and nitrative stress promote diverse pathologic reactions including neurodegenerative disorders, atherosclerosis, chronic inflammation, cancer, and premature labor and stillbirth. These effects occur via sustained inflammation, cellular proliferation and cytotoxicity and via induction of a proangiogenic environment. For example, exposure to the ubiquitous air pollutant ozone leads to generation of reactive oxygen ...
Source: Toxicological Sciences - October 27, 2009 Category: Toxicology Authors: Roberts, R. A., Laskin, D. L., Smith, C. V., Robertson, F. M., Allen, E. M. G., Doorn, J. A., Slikker, W. Tags: REVIEW Source Type: journals

Getting The Facts: Inflammatory Breast CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
October is Breast Cancer Awareness Month, and while it is critically important to raise awareness of breast cancer prevention in general; it is also a particularly important time for us ALL -- whether we are physicians, research scientists, women, or men -- to become acutely aware of a relatively rare, but all too often, poorly understood cancer known as Inflammatory Breast Cancer, or IBC. (Source: Cancercompass News: Breast Cancer)
Source: Cancercompass News: Breast Cancer - October 21, 2009 Category: Cancer & Oncology Source Type: news

Quantitative assessment of DNA hypermethylation in the inflammatory and non-inflammatory breast cancer phenotypes.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, a comparative quantitative methylation profiling of inflammatory breast cancer (IBC) and non-IBC was set up for the identification of tumor-specific methylation patterns. Methylation ratios of six genes (DAPK, TWIST, HIN-1, RASSF1A, RARbeta2 and APC) were measured in benign breast tissues (n = 9) and in tumor samples from non-IBC (n = 81) and IBC (n = 19) patients using quantitative methylation-specific PCR. Median methylation ratios observed in breast cancer (n = 100) were significantly higher than those observed in benign breast tissues for 5 of 6 genes (TWIST, HIN-1, RASSF1A, RARbeta2 and APC). Only one o...
Source: Cancer Biology and Therapy - October 16, 2009 Category: Cancer & Oncology Authors: Van der Auwera I, Bovie C, Svensson C, Limame R, Trinh XB, van Dam P, Van Laere SJ, Van Marck E, Vermeulen PB, Dirix LY Tags: cancer Biol Ther Source Type: journals

Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Reverses Mesenchymal to Epithelial Phenotype and Inhibits Metastasis in Inflammatory Breast Cancer.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: The EGFR pathway is involved in tumor growth and metastasis of IBC. Targeting EGFR through the ERK pathway may represent an effective therapeutic approach to suppress tumorigenicity and prevent metastasis in EGFR-expressing IBC. (Clin Cancer Res 2009;15(21):OF1-10). PMID: 19825949 [PubMed - as supplied by publisher] (Source: Clinical Cancer Research)
Source: Clinical Cancer Research - October 12, 2009 Category: Cancer & Oncology Authors: Zhang D, Lafortune TA, Krishnamurthy S, Esteva FJ, Cristofanilli M, Liu P, Lucci A, Singh B, Hung MC, Hortobagyi GN, Ueno NT Tags: Clin cancer Res Source Type: journals

Podcast: Inflammatory breast cancer symptomsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Inflammatory breast cancer is a rare, aggressive cancer that often doesn't start with a lump. Sponsored by:Chemotherapy.com - http://www.chemotherapy.com (Source: MayoClinic.com Full Feed)
Source: MayoClinic.com Full Feed - October 10, 2009 Category: Consumer Health News Source Type: news

Inflammatory Breast Cancer: New Hopes and Many HurdlesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: JNCI)
Source: JNCI - October 6, 2009 Category: Cancer & Oncology Authors: Rowan, K. Tags: NEWS Source Type: journals

Scientific Presentation Award: The impact of magnetic resonance imaging on surgical treatment of invasive breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: The use of MRI in IBC patients has increased over the past 5 years, without any observable impact on surgical treatment. Similar factors are associated with mastectomy and MRI performance. (Source: American Journal of Surgery)
Source: American Journal of Surgery - September 30, 2009 Category: Surgery Authors: Susanne G. Carpenter, Chee-Chee Stucky, Amylou C. Dueck, Gwen Grimsby, Marina Giurescu, Heidi Apsey, Richard J. Gray, Barbara A. Pockaj Tags: The American Society of breast Surgeons Source Type: journals

Association of low tumor RNA integrity with response to chemotherapy in breast cancer patientsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In this study, we observed that low mid-treatment maximum RIN (but not tumor cellularity) was associated with high chemotherapy drug dose level (P = 0.05) and eventual pathologic complete response (pCR) (P = 0.01). Post-treatment, low maximum RIN was found to be associated with low tumor cellularity (P = 0.004), and low tumor cellularity with pCR (P = 0.01). Post-treatment tumor cellularity was lowest in patients with tumors having high baseline PR levels (P = 0.05). The association of mid-treatment RIN with drug dose level and with pCR suggests that tumor RIN may represe...
Source: Breast Cancer Research and Treatment - September 21, 2009 Category: Cancer & Oncology Tags: breast cancer Research and Treatment Source Type: journals

Inflammatory Breast CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Inflammatory breast cancer (IBC) represents the most virulent form of breast cancer, characterized by involvement of the skin and rapid progression of the disease. Management involves careful coordination of all multidisciplinary modalities, including imaging, systemic chemotherapy, surgery, and radiation therapy. The use of neoadjuvant chemotherapy has contributed significantly to improvement in overall survival since the first descriptions of this entity and has made the role of locoregional therapy, including surgery and radiation critical to continued improvements in this disease. In this article, we examine the unique...
Source: Seminars in Radiation Oncology - September 3, 2009 Category: Cancer & Oncology Authors: Wendy A. Woodward, Massimo Cristofanilli Source Type: journals

Neoadjuvant Chemotherapy for Locally Advanced Breast CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Preoperative systemic therapy is the standard of care in locally advanced breast cancer. In this setting, the intent of preoperative systemic therapy is to expand surgical options and to improve survival. Locally advanced and inflammatory breast cancer have different biological features, but they share the use of preoperative (primary, neoadjuvant) systemic therapy as the initial treatment of choice. The management of these patients necessitates involvement of a multidisciplinary team from the onset and during therapy. The eradication of invasive cancer from the breast and axillary lymph nodes, pathologic complete response...
Source: Seminars in Radiation Oncology - September 3, 2009 Category: Cancer & Oncology Authors: Jennifer Specht, Julie R. Gralow Source Type: journals

Case report of bilateral inflammatory breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
We report an unusual case of bilateral metachronous IBC each with complete clinico-pathological response after treatment with neoadjuvant chemotherapy and surgery on both occasions. (Source: European Journal of Cancer Care)
Source: European Journal of Cancer Care - August 24, 2009 Category: Cancer & Oncology Authors: Y.A. MASANNAT, M. PETER, P. TURTON, A.M. SHAABAN Source Type: journals

18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
To prospectively assess fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) staging and prognosis value in patients with suspected inflammatory breast cancer (IBC).Sixty-two women (mean age 50.7 ± 11.4 years) presenting with unilateral inflammatory breast tumors (59 invasive carcinomas; 3 mastitis) underwent a PET/CT scan before biopsy.PET/CT scan was positive for the primary malignant tumor in 100% and false positive in 2 of 3 benign mastitis. In 59 IBC patients, FDG nodal foci were detected in axillary (90%; n = 53) and extra-axillary areas (56%; n = 33) ipsilateral to the cancer. Compared w...
Source: Cancer - July 29, 2009 Category: Cancer & Oncology Authors: Jean-Louis Alberini, Florence Lerebours, Myriam Wartski, Emmanuelle Fourme, Elise Le Stanc, E. Gontier, O. Madar, P. Cherel, A. P. Pecking Source Type: journals

Oncovista Innovative Therapies, Inc. Announces The Initiation Of Clinical Development Of Adnagen's Breast Cancer Circulating Tumor Cells Diagnostic Technology In Women With High-Risk Locally Advanced Breast CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
SAN ANTONIO -- OncoVista Innovative Therapies, Inc. and AdnaGen Ag announced that The University of Texas M. D. Anderson Cancer Center will collaborate on clinical studies of AdnaGen's molecular based CTC technology in Women with High-Risk Locally Advanced Breast Cancer (LABC) that have completed Neoadjuvant and Local Therapy. "M. D. Anderson is dedicated to helping develop novel approaches that may improve the prognosis of patients with malignant diseases," said Dr. Massimo Cristofanilli, Associate Professor of Medicine and the Director of the Morgan Welch Inflammatory Breast Cancer Research Program and Clinic. Dr. Cristo...
Source: Cancercompass News: Breast Cancer - July 23, 2009 Category: Cancer & Oncology Source Type: news

The Role of Neoadjuvant HER2-Targeted Therapies in HER2 Overexpressing Breast CancersEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
While a number of potential benefits exist for women receiving neoadjuvant systemic therapy for primary operable or inoperable breast cancer, the main advantage, which has been demonstrated consistently, is improved tumour resectability. Given the improvement in outcomes with the adjuvant use of trastuzumab in patients with HER2?positive early stage breast cancer, questions have been raised about the use of trastuzumab in the neoadjuvant setting. This manuscript will review the currently available data and outline suggestions from a panel of Canadian oncologists about the use of trastuzumab and other HER2-targeted agents i...
Source: Current Oncology - July 20, 2009 Category: Cancer & Oncology Source Type: journals

Research Library: Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(Source: Nature Signaling Update)
Source: Nature Signaling Update - July 17, 2009 Category: Research Source Type: info

Strategies to Improve Long-Term Outcome in Stage IIIB Inflammatory Breast Cancer: Multimodality Treatment Including Dose-Intensive Induction and High-Dose ChemotherapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Abstract: Inflammatory breast cancer (IBC) is a rare clinicopathologic entity with a poor prognosis, lagging far behind any other form of nonmetastatic breast cancer. Since the advent of systemic chemotherapy over 35 years ago, only minimal progress has been made in long-term outcome. Although multiple randomized trials of high-dose chemotherapy and autologous progenitor cell transplantation (ASCT) for the treatment of breast cancer have yielded disappointing results, these data are not necessarily relevant to IBC, a distinct clinical and pathologic entity. Therefore, the optimal multimodality therapy for IBC is not well e...
Source: Biology of Blood and Marrow Transplantation - July 9, 2009 Category: Hematology Authors: Claude Sportès, Seth M. Steinberg, David J. Liewehr, Juan Gea-Banacloche, David N. Danforth, Daniele N. Avila, Kelly E. Bryant, Michael C. Krumlauf, Daniel H. Fowler, Steven Pavletic, Nancy M. Hardy, Michael R. Bishop, Ronald E. Gress Tags: Clinical Research Source Type: journals

Rare Breast Cancer Could Be DeadlyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Dear Dr. Gott: A friend of mine was recently diagnosed with inflammatory breast cancer. I have done some initial research online, and www.mayoclinic.com describes it as a "rare but aggressive type of breast cancer that develops rapidly." They also point out that the typical signs of breast cancer -- a lump or suspicious area -- are often absent, and it usually goes undiagnosed until it reaches Stage IV. Could you please explain more about this disorder? Dear Reader: I will certainly try, but because I am neither a gynecologist nor an oncologist, I must defer to more knowledgeable resources for information. According to the...
Source: Cancercompass News: Breast Cancer - June 30, 2009 Category: Cancer & Oncology Source Type: news

Phase II study of neoadjuvant treatment with doxorubicin, docetaxel, and capecitabine (ATX) in locally advanced or inflammatory breast cancer.Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
CONCLUSIONS: ATX every 28 days for four cycles is associated with a modest activity (low pCR rate) in the neoadjuvant setting of LABC. PMID: 19551465 [PubMed - as supplied by publisher] (Source: Breast Cancer)
Source: Breast Cancer - June 23, 2009 Category: Cancer & Oncology Authors: Manga GP, Shahi PK, Ureña MM, Pereira RQ, Plaza MI, Peron YI, Val RG, Carrión JB, Cañón EP, Alfonso PG Tags: breast cancer Source Type: journals

Lapatinib May Work Against Certain Inflammatory Breast CancersEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Women with HER2+ inflammatory breast cancer who haven't responded to other cancer treatments may benefit from lapatinib (Tykerb), according to a recent study. (Source: American Cancer Society :: News and Features)
Source: American Cancer Society :: News and Features - June 18, 2009 Category: Cancer & Oncology Source Type: organizations

Researchers Identify Key Gene In Deadly Inflammatory Breast CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Aggressive, deadly and often misdiagnosed, inflammatory breast cancer (IBC) is the most lethal form of primary breast cancer, often striking women in their prime and causing death within 18 to 24 months. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 15, 2009 Category: Consumer Health News Tags: breast cancer Source Type: news

NYU Langone Medical Center researchers identify key gene in deadly inflammatory breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
(NYU Langone Medical Center / New York University School of Medicine) Aggressive, deadly and often misdiagnosed, inflammatory breast cancer is the most lethal form of primary breast cancer, often striking women in their prime and causing death within 18 to 24 months. Now, scientists from the Cancer Institute at NYU Langone Medical Center have identified a key gene -- eIF4G1 -- that is overexpressed in the majority of cases of IBC, allowing cells to form highly mobile clusters that are responsible for the rapid metastasis that makes IBC such an effective killer. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - June 14, 2009 Category: Cancer & Oncology Source Type: news

Essential role for eIF4GI overexpression in the pathogenesis of inflammatory breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Robert J. Schneider Inflammatory breast cancer (IBC) is the most lethal form of primary breast cancer. IBC lethality derives from generation of tumour emboli, which are non-adherent cell clusters that rapidly spread by a form of continuous invasion known as passive metastasis. In most cancers, expression of E-cadherin, an epithelial marker, is indicative of low metastatic potential. In IBC, E-cadherin is overexpressed and supports formation of tumour emboli by promoting tumour cell interactions rather than adherence to stroma. E-cadherin, a surface component of adherens junctions, is anchored by interaction with p120 cate...
Source: Nature Cell Biology - June 13, 2009 Category: Cytology Authors: Deborah SilveraRezina ArjuFarbod DarvishianPaul H. LevineLadan ZolfaghariJudith GoldbergTsivia HochmanSilvia C. FormentiRobert J. Schneider Tags: Letter Source Type: journals

[Reflection and Reaction] Lapatinib for inflammatory breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Inflammatory breast cancer is characterised by an aggressive nature, a tendency to affect younger women than other breast cancers, a high proportion of local and distant metastases at diagnosis, and low overall survival. Modern treatments have so far failed to substantially affect its poor prognosis. (Source: The Lancet Oncology)
Source: The Lancet Oncology - May 28, 2009 Category: Cancer & Oncology Authors: Peter S Hall, Andrew Hanby, David A Cameron Tags: Reflection and Reaction Source Type: journals

[Articles] Lapatinib monotherapy in patients with HER2-overexpressing relapsed or refractory inflammatory breast cancer: final results and survival of the expanded HER2+ cohort in EGF103009, a phase II studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Inflammatory breast cancer is an aggressive and biologically distinct form with a higher frequency of HER2 overexpression than other breast cancers. For patients with resistance to conventional anthracycline or taxane and trastuzumab treatment, options are limited. Lapatinib, an oral reversible inhibitor of epidermal growth factor receptor tyrosine kinases, previously had a 50% response rate in a cohort of 30 patients with HER2-overexpressing (HER2+) recurrent or anthracycline-refractory inflammatory breast cancer. We aimed to assess efficacy of lapatinib in an expanded cohort of patients with relapsed or refractory HER2+ ...
Source: The Lancet Oncology - May 28, 2009 Category: Cancer & Oncology Authors: Bella Kaufman, Maureen Trudeau, Ahmad Awada, Kimberly Blackwell, Thomas Bachelot, Vanessa Salazar, Michelle DeSilvio, Ronald Westlund, Tal Zaks, Neil Spector, Stephen Johnston Tags: Articles Source Type: journals

Sentinel lymph node biopsy after neoadjuvant chemotherapy in inflammatory breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: The SLN identification and false-negative rates after NAC for IBC were unacceptably high and based on the current findings, SLNB without systematic axillary lymph node dissection is unsuitable in this patient population. (Source: International Journal of Surgery)
Source: International Journal of Surgery - May 26, 2009 Category: Surgery Authors: Samir Hidar, Mohamed Bibi, Olfa Gharbi, Sameh Tebra, Amel Trabelsi, Sadok Korbi, Nouredine Bouaouina, Slim Ben Ahmed, Hédi Khaïri Tags: Original Research Source Type: journals

Rep. Carolyn Mccarthy Introduces Bill To Raise Awareness Of Inflammatory Breast CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
WASHINGTON D.C. -- On Monday, May 4, 2009, Rep. Carolyn McCarthy introduced H.Res. 395, which would support efforts to raise awareness, improve education, and encourage research of inflammatory breast cancer. Inflammatory breast cancer (IBC) is an aggressive form of cancer with a high mortality rate, made more deadly by a lack of awareness and understanding about the disease. IBC results from cancer cells blocking the lymph vessels in the skin of the breast. More often than not, this results in symptoms that are atypical of the majority of breast cancers. In most cases a breast lump and other warning signs that women are t...
Source: Cancercompass News: Breast Cancer - May 26, 2009 Category: Cancer & Oncology Source Type: news

Inflammatory Breast Cancer Can Mimic An InfectionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Dear Dr. Gott: A friend of mine was recently diagnosed with inflammatory breast cancer. I have done some initial research online, and tulsaworld.com/mayo describes it as a "rare but aggressive type of breast cancer that develops rapidly." They also point out that the typical signs of breast cancer -- a lump or suspicious area -- are often absent, and it usually goes undiagnosed until it reaches Stage IV. Could you please explain more about this disorder? Dear Reader: According to the National Cancer Institute, inflammatory breast cancer is very aggressive yet rare. It accounts for 1 percent to 5 percent of all cases of bre...
Source: Cancercompass News: Breast Cancer - May 26, 2009 Category: Cancer & Oncology Source Type: news

Molecular targets for treatment of inflammatory breast cancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
aoto T. Ueno Despite progress in combined-modality treatment with chemotherapy, surgery, and radiation therapy, the long-term outcome for patients with inflammatory breast cancer (IBC) remains poor. Therapies that target vasculolymphatic processes—angiogenesis, lymphangiogenesis, and vasculogenesis—have shown potential in the treatment for IBC, as represented by bevacizumab. Although the therapeutic (Source: Nature Clinical Practice Oncology)
Source: Nature Clinical Practice Oncology - May 25, 2009 Category: Cancer & Oncology Authors: Hideko YamauchiMassimo CristofanilliSeigo NakamuraGabriel N. HortobagyiNaoto T. Ueno Tags: Review Source Type: journals

Drug for Inflammatory Breast CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
An oral medication could help some patients with inflammatory breast cancer. (Source: Medical Headlines From Ivanhoe.com)
Source: Medical Headlines From Ivanhoe.com - April 29, 2009 Category: Consumer Health News Source Type: news

Lapatinib Shows Activity Against Inflammatory Breast CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
New research suggests that lapatinib, an inhibitor of epidermal growth factor receptor tyrosine kinases, may be an effective treatment for HER2-overexpressing relapsed or refractory inflammatory breast cancer. Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 28, 2009 Category: Consumer Health News Tags: Hematology-Oncology Source Type: news

Refractory Inflammatory Breast Cancer May Respond to LapatinibEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
SAN FRANCISCO (MedPage Today) -- Lapatinib (Tykerb) may offer an option for inflammatory breast cancer when other treatments have failed, researchers said. (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 27, 2009 Category: Hematology Source Type: news

Lapatinib Could Be Beneficial In Treating Patients With Aggressive Inflammatory Breast CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
An article published online First and in the June edition of The lancet Oncology reports the findings of a phase II study on inflammatory breast cancer, an aggressive form of the disease representing up to one tenth of malignant breast cancer cases. Dr Stephen Johnston, Royal Marsden Hospital, London, UK, and Dr Bella Kaufman, The Chaim Sheba Medical Center, Tel Hashomer, Israel, and colleagues discuss how lapatinib may be beneficial in the treatment of this form of cancer. (Source: Cancer / Oncology News From Medical News Today)
Source: Cancer / Oncology News From Medical News Today - April 27, 2009 Category: Cancer & Oncology Tags: breast cancer Source Type: news

Drug May Help Against Inflammatory Breast CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Title: Drug May Help Against Inflammatory Breast CancerCategory: Health NewsCreated: 4/27/2009 9:26:00 AMLast Editorial Review: 4/27/2009 (Source: MedicineNet Cancer General)
Source: MedicineNet Cancer General - April 27, 2009 Category: Cancer & Oncology Source Type: consumer

Drug May Help Against Inflammatory Breast CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Title: Drug May Help Against Inflammatory Breast CancerCategory: Health NewsCreated: 4/27/2009 9:26:00 AMLast Editorial Review: 4/27/2009 (Source: MedicineNet Womens Health General)
Source: MedicineNet Womens Health General - April 27, 2009 Category: OBGYN Source Type: consumer

BS12SURGICAL OUTCOMES IN NEO-ADJUVANT CHEMOTHERAPY FOR INFLAMMATORY AND LOCALLY ADVANCED BREAST CANCER EOVER 5 YEARS OF SINGLE INSTITUTION EXPERIENCEEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions: Neo-adjuvant chemotherapy prior to surgery allows good local control and safe reconstruction in locally advanced and inflammatory breast cancer. Smoking cessation should be encouraged prior to surgery to decrease post operative morbidity due to wound complications. Continued follow up of this group would allow examination of and 10 year outcomes. (Source: ANZ Journal of Surgery)
Source: ANZ Journal of Surgery - April 27, 2009 Category: Surgery Authors: T. L. Dean, M. Pitcher Tags: Royal Australasian College of Surgeons Annual Scientific Congress, 69 May 2009, Brisbane, Queensland, Australia. Conference Abstracts < br/ > breast Surgery Program Abstracts Source Type: journals

Immunomedics Reports Preclinical Results of Novel Protein Constructs From Dock-and-LockEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
DENVER, April 22, 2009 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company focused on developing monoclonal antibodies to treat cancer and other serious diseases, today announced the results of four preclinical studies involving new antibody-cytokine conjugates and cytokines site-specifically PEGylated using the Company's and its majority-owned subsidiary, IBC Pharmaceuticals, Inc.'s proprietary Dock-and-Lock method (DNL) for protein engineering. (Source: Medical News (via PRIMEZONE))
Source: Medical News (via PRIMEZONE) - April 22, 2009 Category: Pharmaceuticals Source Type: news

Is [F-18]-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Useful in the Imaging Evaluation of Women With Inflammatory Breast Cancer?Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Commentary on a study on the use of FDG PET/CT for the evaluation of breast cancer that was published in February 2009 in the Journal of Nuclear Medicine. Medscape Radiology (Source: Medscape Ob/Gyn & Women's Health Headlines)
Source: Medscape Ob/Gyn & Women's Health Headlines - April 7, 2009 Category: OBGYN Tags: Radiology Source Type: info

Genetics and Personal Genomics for Personalized Breast Cancer Surgery: Progress and Challenges in Research and Clinical PracticeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Conclusions  Beyond established risk factors, genetic testing allows identification of high-risk patients (BRCA mutation carriers) who may benefit from bilateral mastectomy rather than BCS. Human genetic variation (SNPs/CNVs) and DNA methylation may be relevant for local failures assessment. Technological revolution has opened a new avenue but multiple challenges should be overcome to integrate SNPs/CNVs as markers for IBC/CBC risk-stratification-based personalized surgery. Content Type Journal ArticleCategory Breast OncologyDOI 10.1245/s10434-009-0436-2Authors Dimosthenis Ziogas, Ioannina University S...
Source: Annals of Surgical Oncology - March 26, 2009 Category: Cancer & Oncology Tags: Annals of Surgical Oncology Source Type: journals

Role of the VEGFR3/VEGFD receptor axis in TGF[beta]1 activation of primary prostate cell linesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Reports indicate that vascular endothelial growth factor receptor type 3 (VEGFR3) regulates cellular functions such as invasion, proliferation, and chemo-resistance. However, the exact function of the VEGFR3 signaling axis in prostate epithelial cells is poorly characterized.The goal of this study was to evaluate whether TGF[beta]1 in combination with VEGFD can promote pre-malignant invasive activities of intermediate basal cells (IBC-10a) isolated from human prostate cancer (Gleason score 6).hTERT immortalized IBC-10a cells normally grew as confluent "cobblestoned" monolayers, but treatment with TGF[beta]1 (10 ng/ml for 2...
Source: The Prostate - March 19, 2009 Category: Urology & Nephrology Authors: S.M. Goodyear, S.B. Kheyfets, F.U. Garcia, M.E. Stearns Source Type: journals

Recent advances in systemic therapy. Advances in neoadjuvant (primary) systemic therapy with cytotoxic agentsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Neoadjuvant therapy, also known as primary, induction, or preoperative therapy, is defined as the first systemic treatment a patient receives after cancer is diagnosed, and indicates that subsequent therapies are intended. It was first used in early 1970s for the treatment of inoperable locally advanced or inflammatory breast cancer. Based on a large body of clinical evidence, and the fact, that primary breast cancer is considered today as a systemic disease with a locoregional component, primary systemic therapy (PST) is now increasingly considered for women with operable disease by reducing mortality with lower toxicity,...
Source: Breast Cancer Research - March 17, 2009 Category: Cancer & Oncology Authors: Michael Untch and Gunter von Minckwitz Source Type: journals

Breast Cancer TypesEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A review of several types of breast cancer: ductal, lobular, and inflammatory. Rare types of breast cancer: inflammatory breast cancer, Paget's disease of the nipple. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - March 7, 2009 Category: Cancer & Oncology Tags: health Source Type: consumer

Inflammatory Breast CancerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Definition and description of IBC - Inflammatory Breast Cancer, and how it is related to, and different from, ductal and lobular breast cancer. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - March 7, 2009 Category: Cancer & Oncology Tags: health Source Type: consumer

IBC ImpostorsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Inflammatory breast cancer (IBC) is a rare and very aggressive form of breast cancer. Early detection is critical to proper treatment and survival. So why is IBC often mistaken for other conditions? Learn what the IBC impostors are. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - March 7, 2009 Category: Cancer & Oncology Tags: health Source Type: consumer

Sandi JohnsonEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
went in for a mammogram and came out with a diagnosis of Inflammatory Breast Cancer. She was swept up in the whirlwind of treatments: chemotherapy, surgery, radiation. She owns a gym and is fit. Being diagnosed with breast cancer was a shock. Sandi and her network of support made it through the crisis, and she is now holding steady. Here is Sandi Johnson's breast cancer survivor story. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - March 7, 2009 Category: Cancer & Oncology Tags: health Source Type: consumer